The update was provided alongside full-year results from the group, which has developed rapid assays for Hepatitis-C (HCV) and pathogen detection.
Its HCV product is now registered in 12 countries, while a World Health Organisation is in the process of giving its sign-off for the device, which already has the European CE Mark.
“We remain optimistic that we can achieve WHO pre-qualification by the end of the calendar year,” the company told investors.
Revenues for the 12 months to June 30 rose almost 22% to £2.36mln. A total of £900,000 orders for pathogen kit were received from the US Department of Defense with more to come.
As is common for a company it this formative stage of its commercial progress, genedrive was loss-making. The operating loss was just over £4mln.
More importantly, it had £3.9mln of cash as at September 26 after a successful £6mln fundraiser earlier in the year.
"With two assays now on market and two assays in development, we continue to make good progress on delivering our strategy,” said chief executive David Budd.